These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 18790252)
1. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. Sharma A; Minz M; Singh S Transplant Proc; 2008 Sep; 40(7):2414-5. PubMed ID: 18790252 [TBL] [Abstract][Full Text] [Related]
2. Generic tacrolimus (Pan Graf) in renal transplantation: an experience of 155 recipients in India. Guleria S; Kamboj M; Chatterjee A; Sharma M; Awasthy V; Dinda A; Mahajan S; Bhowmik D; Gupta S; Agarwal SK; Tiwari SC Transplant Proc; 2008 Sep; 40(7):2237-9. PubMed ID: 18790202 [TBL] [Abstract][Full Text] [Related]
3. Tacrolimus (Pan Graf) as de novo therapy in renal transplant recipients in India. Guleria S; Kamboj M; Singh P; Sharma M; Pandey S; Chatterjee A; Dinda AK; Mahajan S; Gupta S; Bhowmik D; Agarwal SK; Tiwari SC; Dash SC Transplant Proc; 2006 Sep; 38(7):2029-31. PubMed ID: 16979989 [TBL] [Abstract][Full Text] [Related]
5. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753 [TBL] [Abstract][Full Text] [Related]
6. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091 [TBL] [Abstract][Full Text] [Related]
7. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Samonakis DN; Mela M; Quaglia A; Triantos CK; Thalheimer U; Leandro G; Pesci A; Raimondo ML; Dhillon AP; Rolles K; Davidson BR; Patch DW; Burroughs AK Transpl Infect Dis; 2006 Mar; 8(1):3-12. PubMed ID: 16623815 [TBL] [Abstract][Full Text] [Related]
8. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259 [TBL] [Abstract][Full Text] [Related]
9. Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant. Elmagd MM; Bakr MA; Metwally AH; Wahab AM Exp Clin Transplant; 2008 Mar; 6(1):42-7. PubMed ID: 18405244 [TBL] [Abstract][Full Text] [Related]
10. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. Sonoda T; Takahara S; Takahashi K; Uchida K; Ohshima S; Toma H; Tanabe K; Yoshimura N; Transplantation; 2003 Jan; 75(2):199-204. PubMed ID: 12548123 [TBL] [Abstract][Full Text] [Related]
11. Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Peddi VR; Kamath S; Munda R; Demmy AM; Alexander JW; First MR Clin Transplant; 1998 Oct; 12(5):401-5. PubMed ID: 9787948 [TBL] [Abstract][Full Text] [Related]
12. European randomised trial of dual versus triple tacrolimus-based regimens for control of acute rejection in renal allograft recipients. Chang RW; Snowden S; Palmer A; Kwan JT; Nicholson M; Kashi SH; Fernando ON; Perner F; Neild GH Transpl Int; 2001 Dec; 14(6):384-90. PubMed ID: 11793035 [TBL] [Abstract][Full Text] [Related]
13. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Waid T; Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546 [TBL] [Abstract][Full Text] [Related]
15. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. Sánchez-Pérez B; Aranda Narváez JM; Santoyo Santoyo J; Fernández-Aguilar JL; Suárez Muñoz MA; González-Sánchez AJ; Pérez Daga JA; Ramírez Plaza CP; Carrasco Campos J; Jiménez Mazure C; Becerra Ortíz R Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171 [TBL] [Abstract][Full Text] [Related]
16. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983 [TBL] [Abstract][Full Text] [Related]
17. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154 [TBL] [Abstract][Full Text] [Related]
18. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus. Rodrigo E; de Cos MA; Fernández-Fresnedo G; Sánchez B; Ruiz JC; Piñera C; Palomar R; Cotorruelo JG; Gómez-Alamillo C; de Castro SS; de Francisco AL; Arias M Transplant Proc; 2005 Nov; 37(9):3819-20. PubMed ID: 16386549 [TBL] [Abstract][Full Text] [Related]
19. Posttransplant diabetes mellitus in renal transplant patients with hepatitis C virus. Sens YA; Silva VD; Malafronte P; Souza JF; Miorin LA; Jabur P Transplant Proc; 2004 May; 36(4):886-8. PubMed ID: 15194304 [TBL] [Abstract][Full Text] [Related]
20. Impact of anti-hepatitis C virus (HCV) antibody on outcomes in renal transplant recipients infected with HCV. Minz M; Sharma A; Das A; Chawla Y Transplant Proc; 2008 Sep; 40(7):2386-8. PubMed ID: 18790242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]